NEW YORK (GenomeWeb) – Illumina has added four genomics startups to its accelerator program, marking its ninth funding round, the company said on Tuesday.
The startups are BioAmp Diagnostics, a precision diagnostics company based in Berkeley, California and focused on antibiotic resistance; Celldom, a North Carolina firm developing single-cell analysis technology; Juno Bio, which is based in the UK and developing vaginal microbiome technology for health and fertility; and TriAxia Health, which is based in Boston and developing a digital health platform to manage patients with rare disease.
As part of Illumina's six-month investment program, the companies have lab and office space at Illumina's San Francisco Bay Area facility, genomics and sequencing expertise, business coaching, and access to capital.
Illumina launched its accelerator program in 2014 and has so far invested in 34 companies.